abc biopply is a Swiss preclinical CRO pioneering humanized multi-organoid disease models to accelerate drug discovery while reducing reliance on animal testing. Using our proprietary 3D CoSeedis™ multi-organoid in-chip technology, we provide scalable, highly standardized organoid assays that enable physiologically relevant drug efficacy, resistance, and safety studies.
Our platform bridges the preclinical complexity gap by combining tissue-level biological relevance with statistically robust experimental throughput, enabling predictive insights earlier in the discovery pipeline.
We collaborate with biotech, pharma, and CRO partners seeking advanced New Approach Methodologies (NAMs), human-relevant disease models, and integrated preclinical studies supporting candidate selection, translational validation, and mechanism-of-action research.
What is your business/industry sector?
Expertise
Humanized multi-organoid models for translational drug discovery
abc biopply offers proprietary 3D CoSeedis™ multi-organoid models for predictive drug discovery, enabling efficacy, safety, and MoA studies in human-relevant systems to improve translational success and reduce reliance on animal models.